ArticleAnnals of surgical oncology2024

Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study.

Nobuhiro Nakazawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.